Wafergen Biosystems said this week that it has reached an agreement with the Luxembourg government to locate its European headquarters in the country.
Wafergen said that the agreement would support the commercialization strategy for its SmartChip Real-Time PCR system, due to launch later this year.
The new Luxembourg location will house Wafergen's European marketing and sales, service and support, distribution, management of any subsidiaries and distributors, IP management, and some R&D activities, the company said.
Wafergen said that it has discussed with the Luxembourg government the potential role of the SmartChip system and other gene-analysis programs in Luxembourg's $200 million biomedical initiative, launched in 2008, which aims to harness genomics technologies to study human health problems.
"This is another important step in our commercialization strategy and combines with the receipt of a CE Mark for the SmartChip system and our collaboration at Ghent University in Belgium to further our international sales expansion," Wafergen Chairman and CEO Alnoor Shivji said in a statement.